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Abstract
Introduction
Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming a diagnostic,
prognostic and predictive tool in cancer patient care. A growing number of gene targets
have been identified as diagnostic or actionable, requiring the development of reliable tech-
nology that provides analysis of multiple genes in parallel. We have developed the InVi-
sion™ liquid biopsy platform which utilizes enhanced TAm-Seq™ (eTAm-Seq™)
technology, an amplicon-based next generation sequencing method for the identification of
clinically-relevant somatic alterations at low frequency in ctDNA across a panel of 35 can-
cer-related genes.
Materials and methods
We present analytical validation of the eTAm-Seq technology across two laboratories to
determine the reproducibility of mutation identification. We assess the quantitative perfor-
mance of eTAm-Seq technology for analysis of single nucleotide variants in clinically-rele-
vant genes as compared to digital PCR (dPCR), using both established DNA standards and
novel full-process control material.
Results
The assay detected mutant alleles down to 0.02% AF, with high per-base specificity of
99.9997%. Across two laboratories, analysis of samples with optimal amount of DNA
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Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files. S4 Table describes all allele fractions (shown
as percentages) for the common low frequency
variants validated/quantified in Horizon Tru-Q 7 and
in the InVision liquid biopsy panel for both
laboratories (one tab per laboratory). S5
Table details the list of variants analyzed in the
Horizon Tru-Q 6 and Horizon Tru-Q 7 dilution
study. S6 Table shows the sensitivity analysis for
all samples. All reportable calls (excluding SNPs
and non-coding changes) made using eTAm-Seq
detected 94% mutations at 0.25%-0.33% allele fraction (AF), with 90% of mutations
detected for samples with lower amounts of input DNA.
Conclusions
These studies demonstrate that eTAm-Seq technology is a robust and reproducible technol-
ogy for the identification and quantification of somatic mutations in circulating tumor DNA,
and support its use in clinical applications for precision medicine.
Introduction
Circulating cell-free DNA (cfDNA) from cancer cells, commonly referred to as circulating
tumor DNA (ctDNA), is known to be present in the plasma of cancer patients. Since the first
report of identical DNA mutations in plasma compared to a patient’s tumor, ctDNA has been
investigated as a tool for cancer diagnosis, detection, prognostication, treatment selection and
monitoring [1–3]. Over the past decade, increasing evidence demonstrates the utility of
ctDNA as a ‘liquid biopsy’ to supplement conventional biopsies for molecular characterization
and monitoring of solid cancers [4–7]. Circulating tumor DNA can be readily accessed from a
non-invasive blood draw, allowing easier access to genomic information from a patient’s
tumor or metastases as the cancer evolves, without the associated expense, complications or
risk to patients during surgery or biopsy. Moreover, tissue testing may not be a viable option
in many patients. In the Iressa Pan-Asia Study (IPASS), a phase III randomized study of gefiti-
nib vs. carboplatin/paclitaxel in patients with pulmonary adenocarcinoma, EGFRmutation
status could only be evaluated in 437/1038 (42%) patients that gave their consent for bio-
marker analyses [8]. The high failure rate may be due to a number of reasons, including insuf-
ficient biopsy material available, because the biopsy was of too poor quality for adequate
analysis, or because surgery was not possible for medical reasons. In such cases, ctDNA can
provide a valuable alternative for molecular stratification to select appropriate therapy. With
the development of targeted therapies, the molecular profile of the cancer has been established
to be informative to select therapies that are more likely to be effective in given patient groups.
For example, tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been
shown to be effective in non-small cell lung cancer (NSCLC) patients carrying activating
EGFR exon 19 deletions or L858R mutations, and vemurafenib is known to be beneficial to
patients with BRAFV600E mutations [9–11]. It has also been shown that it is possible to detect
tumor evolution in plasma ctDNA [6, 12, 13]. EGFR-mutant NSCLC patients can now be
tested and monitored to identify the emergence of newly arising EGFR T790M resistance
mutations, and be effectively treated with osimertinib, a third generation TKI [14–15].
Studies have shown that ctDNA levels often correlate with tumor burden, and provide an
earlier and potentially more reliable measure of treatment response than other clinical bio-
markers, such as CA-15-3 in metastatic breast cancer, and CA-125 in advanced high-grade
serous ovarian cancer [5, 7]. Recent exciting developments have shown that it is possible to use
ctDNA as a tool to assess minimal residual disease [16], and be used to identify mutant DNA
in early stage cancer, although this is much more challenging given the lower number of
mutant molecules present in the bloodstream [17,18]. With such diversity in potential clinical
applications, it is important to use a ctDNA assay that has high sensitivity and specificity, and
can interrogate multiple mutations in parallel to detect, track and monitor clinically-relevant
genomic changes as the cancer evolves. Several techniques are available for the analysis of
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ctDNA. Many of the earlier studies focused on analyzing single mutated regions. Digital PCR
(dPCR) and BEAMing have both been established as sensitive techniques for the detection and
quantification of specific ‘hotspot’ mutant alleles [19, 4]. The cobas EGFR Mutation Test v2 is a
real-time PCR test for the qualitative detection of EGFR exon 19 deletions, L858R and T790M
mutations, and is used to determine which NSCLC patients are eligible for treatment with
erlotinib or osimertinib. The test has gained FDA-approval for testing on both plasma and tis-
sue, making it the first companion diagnostic that allows the use of ctDNA analysis to guide
treatment [20]. The FDA-approved assays, however, are less sensitive than digital PCR, with a
limit of detection (LOD) at>25 copies/mL of plasma [21]. Analysis of single genomic loci is
restricted to a limited number of pre-defined hotspots. To analyse multiple mutations, cfDNA
must first be sub-divided for each assay, reducing the sensitivity of the test and introducing
potential sampling bias for detection of low frequency alleles.
The development of next generation sequencing (NGS) has allowed for a broader applica-
tion of ctDNA analysis. In 2012, Forshew et al. developed TAm-Seq technology, or tagged-
amplicon deep sequencing which, for the first time, enabled interrogation of 6 genes across a
large genomic region spanning 5995 bases to detect low frequency mutations in cell-free DNA
[22]. The assay was evaluated in plasma from patients with high-grade serous ovarian cancer,
and shown to have 97% sensitivity and specificity for detection of mutations at 2% allele frac-
tion (AF), and was able to identify mutations down to 0.14% AF. Analysis of clinical samples
showed that it is possible to use TAm-Seq technology to assay multiple mutations in parallel to
monitor tumor dynamics, identify de novo mutations direct from patient cfDNA, and identify
the origin of metastatic relapse. Since this time, other NGS technologies have been imple-
mented for analysis of ctDNA, including the use of hybrid capture and the introduction of
panel assays that use molecular barcodes to enable error suppression [6, 23, 24]. The ideal
ctDNA assay needs to have high sensitivity and specificity, have good turnaround times and
target clinically-relevant and clinically actionable genes. This will enable oncologists to make
clear treatment decisions based on molecular profiling information, according to cancer care
guidelines and used in conjunction with other clinical observations.
Here we describe the development of the InVision liquid biopsy platform which utilizes
enhanced TAm-Seq (eTAm-SeqTM) technology for the identification of low frequency muta-
tions in ctDNA. The assay has been expanded to target hotspots and entire coding regions
from 35 cancer-related genes, utilizing a primer design strategy that allows for amplification of
highly fragmented DNA, typical of ctDNA. The calling algorithm has been revised, and in
addition to improved detection of single nucleotide variants (SNVs) and short insertions/dele-
tions (indels), it also identifies copy number variants (CNVs). The library preparation process
has been adapted to remove the use of microfluidics and to reduce the background error rate.
We present analytical validation of the InVision liquid biopsy platform across two laboratories
to demonstrate its reproducibility and to support the use of this platform in clinical applica-
tions. We compare the performance of eTAm-Seq technology and digital PCR by analysis of
sheared cell-line reference standard DNA and novel full-process control material developed by
LGC and Horizon Discovery.
Materials and methods
Analytical validation of eTAm-Seq technology
To assess the performance of the eTAm-Seq technology, analytical validation studies were per-
formed in two laboratories within the scope of CLIA (Laboratory 2) and ISO 15189:2012 qual-
ity standards (Laboratory 1). Next-generation sequencing libraries were prepared using
eTAm-Seq technology, analysing sheared reference standard DNA and cfDNA extracted from
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control plasma from presumed healthy controls. Healthy control samples used in this study
were obtained on a commercial basis, from BioreclamationIVT (US) and Seralab (UK). Cell-
free DNA (cfDNA) was extracted from 5 mL plasma using a QIAamp Circulating Nucleic
Acid kit (Qiagen) as previously described [22], incorporating an internal control to monitor
extraction efficiency. cfDNA and the internal control were both quantified by dPCR, using
either the Fluidigm Biomark or Biorad QX200, with a 108 bp assay targeting a region of ribo-
nuclease P/MRP subunit p30 (RPP30) gene (Forward = 5’-GGAGGTGGAGGAGGAGGATA-
3’; Reverse = 5’-ACGGAATACAGAACCCATGACT-3’; Probe = 5’-FAM/AGCCTTGAG/
ZEN/ AGACGAGAACCTGT/IABkF Q-3’) and an assay targeting the internal control, as
previously described [22]. Yields were expressed as amplifiable copies (AC) per 10 mL blood.
Preparation of sheared cell-line reference standard DNA for analytical validation stud-
ies. Horizon Tru-Q 6 (2.5% Tier) and Tru-Q 7 (1.3% Tier) reference cell-line DNA samples
(Horizon Discovery), carrying cancer-related mutations at known allele fractions, were
sheared to ~200 bp by acoustic shearing (Covaris) to mimic fragmented cfDNA. Tru-Q 6 con-
tains a mix of 20 isogenic genetically-engineered cell lines with known engineered and endoge-
nous mutations predominantly at ~2%-2.5% AF (range: <2%-30% AF), and Tru-Q 7 contains
a mix of 40 cell lines with known mutations predominantly at ~1%-1.3% AF (range: <1%-30%
AF). Dilutions were prepared using sheared Horizon Tru-Q 0 wild-type DNA as diluent.
InVision liquid biopsy tumor profiling panel. The InVision liquid biopsy platform uti-
lizes an enhanced version of TAm-Seq technology to identify and quantify low frequency
tumor-derived SNVs and indels in cfDNA. The technology is also able to identify CNVs in
EGFR, ERBB2 (also known as HER2), FGFR1 and MET [25]. Full analytical validation of CNVs
is not included in this study. The assay targets 35 cancer-related genes spanning 10.61kb, using
primers designed to hotspots and entire coding regions of interest. Covered regions were cho-
sen to maximise the mutation yield for common cancer types primarily NSCLC, focusing on
clinically actionable mutations. We therefore included oncogenes EGFR, BRAF,KRAS, ERBB2,
MET (exon 14), U2AF1,CTNNB1, EGFR/MET amplifications as well as tumour suppressor
genes TP53, STK11, PTEN. We further included key regions of ESR1/GATA3, as well as
ERBB2/FGFR1 amplifications, and the most common mutation hotspots in common carcino-
mas as defined by COSMIC frequencies. The panel was designed optimizing primers for
amplification of fragmented DNA with amplicon sizes ranging from 72bp-154bp. The primers
were selected based on factors including GC content, similar Tm (target 60˚C), avoidance of
primer dimer, avoidance of off-target products and avoidance of SNPs. Fig 1 shows an over-
view of the InVision liquid biopsy tumor profiling panel, and S1 Table provides detail of the
exonic regions covered.
Library preparation using eTAm-Seq technology. eTAm-Seq technology is based on
methods previously described [22, 25,26], with an optimized assay workflow utilizing multi-
plex PCR to enable high-throughput library preparation without the use of microfluidics. Next
generation sequencing libraries were prepared using a two-step multiplex PCR amplification
process incorporating replicate and patient-specific barcodes and Illumina sequencing adap-
tors. Different input amounts of DNA were used to assess the performance of the assay, using
either 2,000 AC (low), 8,000 AC (medium) or 16,000 AC (high) input (~6.6ng to 53ng of
amplifiable DNA). All regions were analysed multiple times using a fixed DNA input range for
all samples to enable error correction [26]. As each sample is analysed multiple times, false
positive and true positive calls can be readily identified, providing a robust analytical pipeline
[22, 26]. After target enrichment, amplified regions were purified using SPRISelect beads
(Beckman Coulter) following the manufacturer’s protocol. Samples were quantified using the
LabChip GX touch and DNA high sensitivity assay. Quantified samples were then pooled to
generate a normalized library of 12 nM. This library was quantified using the Kapa Library
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Quantification Kit, and 1.8 pM libraries analysed on an Illumina NextSeq 500 (300 cycle PE)
with 5% PhiX to monitor sequencing performance.
Data analysis. Sequencing files were analysed using the Inivata Somatic Mutation Analy-
sis (ISoMA) pipeline to identify SNVs, CNVs and indels. A minimum Phred quality score of
30 for each base was required for inclusion in the analytics. The pipeline clipped primers and
merged paired-end reads into synthetic reads (using Flash v1.2.11). A minimum Phred quality
score of 2 was assigned to discordant positions at the merging step. Default settings were used
for Flash and a Phred quality score of 2 was assigned to mismatched base pairs. These synthetic
reads were subsequently aligned to the reference genome using BWA (v0.7.12). Samples pass-
ing sequencing QC were kept for further analysis.
To enable variant calling, the background noise for each potential SNV was compared to
the variability observed from a set of control samples [22]. The same statistical principle was
used for indels using samples from the same batch of samples in order to enable appropriate
background calibration. In addition, each run was assessed using positive and negative
Fig 1. InVision liquid biopsy tumor profiling panel. The coverage per gene is indicated, including hotspots, comprehensive or full coverage of coding
regions (70%–100% tiling coverage) and CNVs. SNVs = Single Nucleotide Variants; Indels = short insertions or deletions; CNVs = Copy Number
Variants.
https://doi.org/10.1371/journal.pone.0194630.g001
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controls. Common single nucleotide polymorphisms (SNPs) were used to identify potential
cross sample contamination, as well as rule out potential swaps for longitudinal studies involv-
ing multiple samples from the same patient. The final determination of a call integrated the
data across replicates for the sample within a maximum likelihood framework. Variants were
annotated using the variant effect predictor [27] based on the canonical transcript for each
gene. SNVs and indels that resulted in coding and splice-site mutations were reported. For
CNVs, a normalized measure of read depth that corrects for sample and amplicon effects was
used to infer the number of DNA copies. A mutation calling report was generated providing a
comprehensive summary of somatic alterations identified.
Comparison of performance of eTAm-Seq technology and digital PCR by
analysis of novel full-process control material
Preparation of pooled plasma. Sixteen human plasma samples of ~20 mL each from 6
male and 10 female donors were obtained from Seralab (UK). All plasma samples had under-
gone a second centrifugation step of 1,000 x g for 10 minutes at 4˚C, following initial centrifu-
gation from whole blood. Samples were stored at -80˚C upon receipt. Samples were pooled
and homogenized using a roller mixer for 30 minutes at 4˚C followed by preparation of 5.0
mL aliquots which were frozen at -80˚C.
cfDNA reference standards. Multiplex I cfDNA Reference Standards (Horizon Discov-
ery) were generated from genomic DNA isolated from isogenic cell-lines, and fragmented to
~160 bp by acoustic shearing (Covaris). The standards, containing 8 known mutations in
EGFR (L858R, Δ746–750, T790M, V769-D770insASV), KRAS (G12D), NRAS (A59T, Q61K)
and PIK3CA (E545K), were diluted to 8 ng/μL for spiking into plasma.
cfDNA extraction. Following thawing of plasma aliquots, 50 μL (400 ng) of Multiplex I
cfDNA Reference Standard containing target mutations at ~5%, ~1%, ~0.1% AF or 100%
wild-type DNA was added to 5 mL pooled plasma and mixed by vortexing for 10 seconds.
DNA was extracted from plasma samples using the QIAamp Circulating Nucleic Acid Kit
(Qiagen) and eluted in 50 μL AVE buffer. Replicate extractions (n = 6) were performed for all
four levels of Reference Standard (5%, 1%, 0.1% and 100% wild-type) and plasma only controls
over 3 days (2 extractions per day). Extracts were divided into two aliquots (25 μL) and frozen,
with one aliquot analysed by the eTAm-Seq technology and one aliquot analysed by digital
PCR.
Mutational analysis. Samples were analysed using the eTAm-Seq technology in Labora-
tory 1 using an average of 12,450 AC per reaction. Digital PCR analysis was performed using a
QX200 droplet dPCR system (Bio-Rad) with a C1000 Touch Thermal Cycler (Bio-Rad) at
LGC. KRAS G12/WT and EGFR L858R/WT mutations were assessed using PrimePCR assays
(Bio-Rad) and custom designed assays were used targeting NRASA59T/WT and PI3KCA
E545K/WT (S2A–S2C Table). Primers and BHQplus probes for custom assays were supplied
by BioSearch and diluted in 1 x TE pH 8.0 (Sigma). Reactions (20 μL) were prepared (with
10% excess) and contained ddPCR Supermix for Probes with no dUTP (Bio-Rad), 20x primer/
probe mix, 4 μL cfDNA extract (n = 1 per target mutation) with the remaining volume nucle-
ase-free water (Ambion). Non-spiked Multiplex I cfDNA Reference Standards (32 ng/reac-
tion) were analysed alongside the spiked extracts as controls (n = 3). Data was analysed using
QuantaLife (Bio-Rad, version 1.6.6.0320) with classification of single positive, double positive
and negative droplets as shown in S1A–S1E Fig. Copy number concentration was calculated
based on a partition volume of 0.85 nL.
Calculation of LOD for dPCR assays. The LOD of dPCR assays were calculated using the
approach described in Whale et al. based on modelling two binomial distributions, combining
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a 5% probability of a false positive (α = 0.05) with a 5% probability of a false negative (β = 0.05)
[28]. The false positive rate (FPR) for each assay was calculated from analysis of the 100% WT
Multiplex I cfDNA Reference Standard (n = 6 reactions, 80 ng per reaction). The ‘critical level’
is the 95th percentile for a binomial distribution with n trials and probability given by the false
positive rate per droplet (λ), where n is the mean number of droplets from the data. The LOD
expressed as mutant copies per reaction is given by n ×–ln(1-p) where p is the probability of
success for the binomial distribution with n trials and where the 5th percentile equals the criti-
cal level. The LOD expressed as AF% is the previous value relative to the total number of target
copies (i.e. n times the mean concentration per droplet (λ) of the wild-type target, plus the
mutant value) (S3 Table).
Results
Analytical validation of the eTAm-Seq technology
Analytical validation studies were performed to assess sensitivity of the eTAm-Seq technology
for detection of SNVs and indels. Horizon Tru-Q 6 Tier 2.5% and Tru-Q 7 Tier 1.3% cell-line
reference standard DNA, carrying mutations at known AF were sheared to ~200bp to approxi-
mate cfDNA. There are 21 mutations present in Tru-Q6, and 38 mutations in Tru-Q7 targeted
by the InVision liquid biopsy tumor profiling panel. Dilutions were prepared using Horizon
Tru-Q 0 wild-type DNA as diluent. Data previously published showed that concentrations of
cfDNA in plasma of cancer patients was >1.65 ng/mL in 99% of patients, >6.6 ng/mL in 80%
of patients, and>13.2 ng/mL in nearly 50% of patients [29]. This is consistent with cfDNA
amounts in 10 mL blood samples (approximately 4~4.5 mL of plasma) from NSCLC patients
which were previously shown to contain >2,000 AC (~6.6 ng) in >95% of samples, >8,000
AC (~26.4 ng) in>69% of samples and>16,000 AC (~52.8 ng) in>40% of samples [25]. Dilu-
tions were therefore performed to prepare low (2,000 AC), medium (8,000 AC) and high
(16,000 AC) input amounts. Limit of Detection (LOD), inter-operator and inter-laboratory
variability were assessed by performing the assay across two laboratories by 6 operators on dif-
ferent days and sequenced on different NGS runs. Each operator independently performed the
entire process, and one of the operators performed the assay at each of the two laboratories.
Multiple assays were performed in each laboratory at different dilution levels, as shown in
Table 1.
Analysis using eTAm-Seq technology showed that the assay had high sensitivity (Fig 2). In
Laboratory 1, sensitivity was 100% (90% confidence interval (CI): 99.01%-100%) in low input
samples at 2%-2.5% AF, 99.17% (90% CI: 97.40%-99.85%) in medium input samples at 1%-
Table 1. Details of analytical validation experiments performed to assess sensitivity of the eTAm-Seq technology,
including range of input DNA (AC), AF (%), number of sample repeats per operator, and number of operators
per laboratory.
Input DNA (AC) AF (%) Number of repeats/operator Number of operators/laboratory
16,000 0.25%-0.33% 4 3
8,000 1%-1.3% 3 3
2,000 2%-2.5% 7 3
8,000 0.5%-0.65% 3 3
8,000 0.25%-0.33% 3 3
8,000 0.13%-0.16% 3 3
8,000 0.06%-0.08% 3 3
 AF shows indicative ranges for Tru-Q reference material, full list of values presented in S4 Table.
https://doi.org/10.1371/journal.pone.0194630.t001
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Fig 2. Plot showing sensitivity and inter-operator variability of eTAm-Seq technology using low, medium and high input DNA. Experiments were performed in
two laboratories (Laboratory 1 –upper; Laboratory 2 –lower) by different operators, performed on separate days and different NGS runs.
https://doi.org/10.1371/journal.pone.0194630.g002
Table 2. Sensitivity of the eTAm-Seq technology with 8000 amplifiable copies of DNA input per sample.
Laboratory 1 Laboratory 2
AF (%) Sensitivity (%) 90% CI (Lower) 90% CI (Upper) Sensitivity (%) 90% CI (Lower) 90% CI (Upper)
1%-1.3% 99.17 97.40 99.85 100.00 98.96 100.00
0.5%-0.65% 99.63 98.26 99.98 97.66 95.43 98.97
0.25%-0.33% 89.17 85.29 92.30 90.28 86.91 93.00
0.13%-0.16% 69.26 64.31 73.89 67.71 62.88 72.26
0.06%-0.08% 37.41 32.50 42.52 30.86 26.10 35.95
 AF shows indicative ranges for Tru-Q reference material, full list of values presented in S4, S5 and S6 Tables.
https://doi.org/10.1371/journal.pone.0194630.t002
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1.3% AF, and 95.45% (90% CI: 93.09%-97.18%) in high input samples at 0.25%-0.33% AF.
Comparable results were seen in the second laboratory, with a sensitivity of 99.7% (90% CI:
98.6%-99.98%) in low input samples, 100% (90% CI: 98.97%-100%) in medium input samples,
and 92.71% (90% CI: 90.14%-94.77%) in high input samples.
To further assess the limit of detection (LOD) using medium input of 8000 amplifiable cop-
ies of DNA, a dilution series was created by spiking sheared Horizon Tru-Q 7 into Tru-Q 0 ref-
erence standard to approximate an AF range of 0.06%-1.25% AF. In Laboratory 1, 99.17%
mutations were detected at 1%-1.3% AF, 99.63% at 0.5%-0.65% AF, 89.17% at 0.25%-0.33%
AF, 69.26% at 0.13%-0.16% AF and 37.41% at 0.06%-0.08% AF. Comparable results were seen
in Laboratory 2 (Table 2, S2 Fig, S4 Table, S5 Table) and for all samples (S6 Table).
Across the two laboratories using 8000 amplifiable copies of input DNA, 98.65% of muta-
tions were detected at 0.5%-0.65% AF. For the 0.25%-0.33% dilution range, the sensitivity was
89.73%. The lowest frequency mutation identified was an EGFR indel (ΔE746-A750) detected
at 0.02% AF.
Assessment of quantitative performance of eTAm-Seq technology by
comparison with digital PCR analysis of reference cell-line DNA carrying
mutations at known allele fraction
In order to determine the quantitative performance of the eTAm-Seq technology, data was
compared with allele fractions generated by digital PCR analysis of Horizon Tru-Q 6 and Tru-
Q 7, supplied by the manufacturer. As can be seen in Fig 3A and Fig 3B, there is good concor-
dance between AFs determined by the eTAm-Seq technology and digital PCR analysis of 21
mutations present in both the InVision liquid biopsy tumor profiling panel and Tru-Q 6, and
analysis of 38 common mutations in Tru-Q 7. This demonstrates the quantitative accuracy of
eTAm-Seq technology for reliable detection of mutations at low allele frequency.
Assessment of specificity of the eTAm-Seq technology by analysis of
plasma from presumed healthy donors
Tru-Q6 or Tru-Q7 reference DNA contains additional mutations outside of the validated
mutations listed in these cell-line mixes, and is therefore not suitable for assessing specificity.
Plasma samples from 79 presumed healthy donors were therefore analysed using eTAm-Seq
technology to assess specificity. This analysis identified five low frequency coding mutations,
all at0.5% AF: three located in TP53 [L308L at 0.19% AF (Laboratory 1); Y220C at 0.5% AF
and P27L at 0.5% AF (Laboratory 2)] and two in GATA3 [T323T at 0.1% AF and T419T at
0.317% AF (Laboratory 2)]. Sufficient material was available to enable re-extraction of plasma
cfDNA from the same blood draw in four out of five cases (all but GATA3 T419T). Analysis by
eTAm-Seq technology was repeated for these 4 samples. Re-analysis confirmed the initial call
for three of the four samples, failing only to detect the TP53 L308L change originally identified
at 0.19% AF. This resulted in two potential false positives, one is unconfirmed, and the other
may be a false-negative of the replicate assay at0.19% AF. The identification of 2 potential
false positives in 79 healthy samples amounts to a per-base specificity of at least 99.9997%
(95% confidence interval, 99.9989% to 99.99996% per-base specificity).
Analysis of novel full-process control material using eTAm-Seq technology
and digital PCR
To explore the performance of a novel full-process control with spiked DNA reference stan-
dards and assess the ability of the eTAm-Seq technology to identify low frequency mutations,
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5 mL aliquots of pooled plasma from 6 male and 10 female presumed healthy donors were
spiked with 400ng Multiplex I cfDNA Reference Standard. This reference standard, acousti-
cally sheared to 160bp to mimic cfDNA, is derived from well-characterized isogenic cell-lines
and contains 8 target mutations at ~5%, ~1% or ~0.1% AF. 100% wild-type DNA from non-
modified cell-lines containing 100% wild-type DNA was used as a control. By spiking into
plasma containing background DNA, the resulting mix would be expected to contain lower
AFs than the original standards. For each of the four levels, replicate cfDNA extractions
(n = 6) were performed over 3 days, together with replicate plasma-only controls. The cfDNA
was sub-divided into two for analysis by both eTAm-Seq technology (Laboratory 1) and dPCR
(LGC). dPCR analysis was performed targeting hotspot mutations in EGFR L858R, KRAS
G12D, NRASA59T and PIK3CA E545K. The observed extraction efficiency was highly repro-
ducible between replicates, with ~50% recovery of the spike-in (S3 Fig). More variability was
observed in the 0.1% AF-spiked sample, likely due to sampling noise when quantifying small
numbers of mutant molecules. The extraction efficiency was slightly lower than has previously
been reported (60%-80% recovery) for measurement of a spike-in control [30]. Quantification
of the<5% AF and<1% AF samples using the eTAm-Seq technology and dPCR spiked
Fig 3. Plot showing allele fractions determined by analysis with eTAm-Seq technology (blue boxplot) and digital PCR (red cross) for analysis of mutations present in
both the InVision liquid biopsy tumor profiling panel and (A) Tru-Q 6 and (B) Tru-Q 7.
https://doi.org/10.1371/journal.pone.0194630.g003
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plasma showed good concordance (Fig 4). The small deviation in AF observed in the contrived
control samples may be related to differences in DNA fragment sizes between the sheared
mutant DNA and the wild-type donor plasma, which may differentially affect the results of the
two methods. Both methods showed good precision with low %CV for all 4 mutations in anal-
ysis of plasma spiked with 5% and 1% AF reference standard (S4 Fig).
100% of mutations known to be present in the<5% and<1% AF pool were detected by
both eTAm-Seq technology and dPCR (S5 Fig, S7 Table). An additional 5 coding mutations in
BRAFV600E (20.07% AF), CTNNB1 S33Y (14.72% AF), PIK3CA H1047R (13.98% AF), STK11
Q123Q (13.37% AF) and EGFR G719S (13.31% AF) were detected using the eTAm-Seq tech-
nology. These mutations were all confirmed to be present by exome sequence analysis of the
original isogenic cell-lines that the reference standards were derived from. In the<0.1% spiked
sample, across the 4 overlapping mutations analysed by both methods in the 6 replicate extrac-
tions, amplicon sequencing detected 11/24 mutations whilst dPCR detected 16/24. Overall, 25/
48 (53%) mutations in the <0.1% AF sample were detected using eTAm-Seq technology, as
expected given the limit of detection for the assay and stochastic sampling effects. Two poten-
tial false positives were identified: TP53 F113V (GRCh38 chr17:7676032 A>C) at 0.15% AF
and GNA11 R214M (chr19:3118959 G>T) at 0.1% AF. The GNA11 mutation was possibly
caused by 8-oxoguanine (8-oxoG) lesions created during the shearing process used to create
the original reference standard DNA. Many of the samples with spiked fragmented DNA had
high background at this position and at other G bases, whilst non-sheared plasma did not
show an aberrant base both in this run and in previous experiments. The TP53mutation was
observed significantly above normal background, and may be a false positive or a true low fre-
quency variant.
Discussion
It has long been known that genomic alterations in cancer can be detected in the plasma of
cancer patients in the form of circulating tumor DNA. Increasing evidence indicates clinical
utility of ctDNA as a diagnostic, prognostic and predictive tool with potential application
Fig 4. Quantitative agreement of 5% AF and 1% AF reference standard spiked into plasma, and measured by eTAm-Seq technology and dPCR. Mean mutant AF
(%) ± SD are displayed for each technology (n = 5 (5% AF standard); n = 6 (1% AF standard)). By spiking into plasma containing background wild-type DNA, the
resulting mix was confirmed to contain lower AFs than the original reference standards (original mutant AF values 5% standard: 5% (EGFR); 6.3% (KRAS,NRAS,
PIK3CA); 1% standard: 1% (EGFR), 1.3% (KRAS,NRAS, PIK3CA). (1 data point omitted due to anomalous extraction efficiency).
https://doi.org/10.1371/journal.pone.0194630.g004
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throughout the continuum of cancer care. FDA approval of the first companion diagnostic
permitting ctDNA-based mutation detection, and the emergence of several ctDNA-guided
clinical trials [31–33] signals growing acceptance of its utility. ctDNA analysis offers important
advantages over profiling single biopsies taken during invasive surgery, often many months or
years before clinical progression. ctDNA enables repeat sampling and molecular assessment of
tumor evolution during patient treatment, which may help guide subsequent therapy [5, 15].
Advances in NGS have shown it is possible to monitor tumor dynamics and assess evolution
in plasma by analysis of multiple mutations in parallel across serially-collected samples, rather
than focusing on single hotspot mutations. Digital PCR analysis of multiple mutations is possi-
ble to a limited degree but requires sub-dividing DNA into different assays. When large
amounts of DNA are available, this can be achieved but where DNA is limited, such as in the
analysis of cfDNA, this results in sampling noise and loss of sensitivity as rare mutant mole-
cules are missed. NGS analysis, with a sensitive and appropriately validated platform, circum-
vents these issues, providing substantially more information on somatic alterations present in
the bloodstream, which can be used to guide subsequent cancer therapy.
Currently, there is a limited but growing number of clinically actionable gene targets. The
hope is that future advances will result in the development of new immunotherapies and tar-
geted treatments effective against additional somatic alterations known to be present. One
important factor in the development of a clinically useful ctDNA assay is to strike the right bal-
ance in the size of the genomic region analysed to enable optimal test sensitivity and specific-
ity. By increasing the size of the genomic region covered, the correction for false positives
needs to be more stringent. Hybrid capture-based enrichment methods have enabled analysis
of focused genomic regions up to whole exomes [6, 23, 24]. However, analysis of larger regions
either requires expensive high depth sequencing to identify low frequency mutations, or a
compromise on depth and associated reduction in sensitivity. Hybrid capture can be used to
target more focused regions but this leads to a high proportion of off-target sequencing reads.
Like the sampling noise challenge for dPCR described above, a key limit for all NGS methods
developed for cfDNA analysis is the fraction of DNA molecules successfully analysed. Through
PCR enrichment, with suitably short amplicons, amplicon-based sequencing can achieve sen-
sitivity comparable to dPCR by amplifying and thereby sampling the majority of cfDNA mole-
cules accessible to PCR amplification. Since samples need not be split into multiple assays, the
effective sensitivity of amplicon-based sequencing may even exceed that of dPCR [20, 34, 35].
Hybrid capture library preparation methods are not restricted to amplifying regions contain-
ing both priming sites. However, they require considerable pre-processing prior to enrichment
or PCR-based amplification and therefore may lose a significant proportion of molecules dur-
ing library preparation stages, particularly during adaptor ligation [36]. This is important for
analysis of ctDNA given the low frequency of tumor-derived DNA molecules present in
patient plasma, particularly in earlier stage cancer.
Here, we have described the InVision liquid biopsy platform which utilizes enhanced
TAm-Seq technology for the identification of low frequency mutations in cell-free DNA. This
amplicon-based method has been carefully optimized for efficient amplification from limited
amounts of fragmented plasma DNA. The focused gene panel targets 35 clinically actionable
and clinically-relevant genes, providing coverage of critical regions in 31 genes and near com-
plete coverage of 4 genes of clinical significance. Analytical validation of the assay demon-
strates high sensitivity and specificity for detection of low frequency mutations with 94.08% of
mutations detected at 0.25% - 0.33% allele fraction (AF) with optimal DNA input, with a per-
base specificity of 99.9997%. Validation across two laboratories demonstrates its reproducibil-
ity and supports its use in clinical applications. In addition, the assay is highly quantitative,
demonstrating excellent concordance with digital PCR analysis of commercial cell-line
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reference standard DNA, and novel full-process control material developed by LGC and Hori-
zon Discovery, that carry cancer-related mutations at known allele fractions.
Using this assay, mutant alleles were detected down to 0.02% AF, with>30% sensitivity for
detection at 0.06% AF (1 mutant DNA copy in 1600 molecules). This study identifies two chal-
lenges when assessing assay specificity using either individual donors or acoustically-sheared
commercial reference standards for analysis of low frequency mutations in ctDNA using an
ultra-sensitive test. During analysis, five mutations at0.5% AF were identified in presumed
healthy donors, yet when 4 samples with sufficient material were re-analysed, the same muta-
tions were repeatedly identified in 3, indicating these were true positives; the 4th change was
originally detected at a low allele fraction of 0.19% so possibly missed on repeat due to its low
allele fraction. Somatic mutations have previously been detected in presumed healthy individ-
uals, and may represent pre-malignant mutations that accumulate prior to cancer or during
the aging process [37], or changes that have arisen during clonal hematopoiesis [37, 38] or
could originate from undetected tumors. More studies are needed using orthogonal assays
with similarly high sensitivity to determine if changes are truly present. Using the commercial
reference standard, a GNA11 R214M G>T mutation was identified along with a signature of
high background G>T/C>A errors at other bases. This is consistent with 8-oxoguanine
(8-oxoG) lesions created during the acoustic shearing process or potentially evolution and het-
erogeneity of the cell lines. The phenomenon of G>T/C>A transversion artifacts was first
identified by Costello et al. [39, 40], and highlights the potential risk of using acoustically-
sheared DNA to validate specificity of sensitive ctDNA NGS-based assays capable of detecting
low frequency sequence aberrations. One solution may be to limit the use of sheared material
to the assessment of assay sensitivity, since this material performed well at the loci that were
defined and tested for this purpose, and use donor (healthy volunteer) DNA for broader speci-
ficity assessment (given the caveats previously mentioned and repeat or orthogonal analysis
for confirmation). Alternatively, different mechanisms could be investigated to fragment com-
mercial reference standard DNA, such as enzymatic fragmentation, which may potentially
introduce less DNA damage.
Given the restrictive requirement to immediately process EDTA-collected blood to plasma
to prevent leukocyte lysis, it is important to validate the eTAm-Seq technology using blood col-
lected into Streck Cell-free DNA BCT tubes. These tubes contain a proprietary cell preservative
which stabilizes nucleated blood cells preventing contamination with background wild-type
DNA. Analysis of the eTAm-Seq technology in EDTA and Streck tubes collected at the same
time from patients has previously been presented [40], and showed high technical reproduc-
ibility between two independently processed blood tube types, indicating use of either tube
type is suitable for clinical blood collection using this technology. The Streck Cell-free DNA
BCT tubes provide a robust alternative to enable delayed and centralized processing which will
help standardize pre-analytic factors during blood collection, and provides improved feasibil-
ity for introduction into routine ctDNA testing in the clinic.
In support of the use of the InVision liquid biopsy platform in clinical applications, data
has previously been reported demonstrating a high level of concordance between this platform
and dPCR in mutations detected in 35 patients with advanced breast cancer [41]. With 100%
and 96% agreement for mutation detection in ESR1 and PIK3CA respectively, amplicon
sequencing identified additional mutations not covered by dPCR analysis and therefore sub-
stantially more mutations per patient which have possible clinical relevance. There was 100%
concordance in the detection of HER2 amplifications when compared to IHC and/or FISH of
metastatic tumors [42]. Furthermore, Fribbens et al. demonstrated good concordance of
eTAm-Seq technology with dPCR, with high levels of genetic heterogeneity and frequent sub-
clonal mutations in advanced breast cancer patients progressing on first-line aromatase
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inhibitor therapy [42]. In this study, ESR1mutations were detectable in plasma median of 6.7
months before clinical progression. Another study compared the detection of mutations in
EGFR between plasma and tissue and across platforms, and found amplicon-based plasma
NGS to have exquisite sensitivity and specificity, with excellent quantitative concordance with
an optimized dPCR assay [43]. Remon et al. have previously demonstrated the use of eTAm-
Seq technology to aid in selection of targeted treatment in a prospective cohort of 48 EGFR-
mutant advanced NSCLC patients with acquired resistance to EGFR TKIs, and without an
available tissue biopsy [15]. cfDNA analysis identified resistance mutations in EGFR T790M at
frequencies as low as 0.1% AF, and the study was able to demonstrate the benefit of osimertinib
treatment in these patients. Strikingly, of the seven cases in that study with best response
(decrease of 50% or more in size), three cases had T790M detected at<0.25% AF. Use of a less
sensitive assay would miss such low frequency alleles.
Taken together, these studies demonstrate that the InVision liquid biopsy platform is a
highly sensitive, quantitative and reproducible platform for detection of low frequency clini-
cally-relevant cancer mutations in cell-free DNA. Additional larger cohorts are currently being
analyzed to support clinical validation and clinical utility of the test and provide evidence to
support introduction into routine testing for patient management.
Supporting information
S1 Fig. A-E dPCR data plots for analysis of full-process control samples. (A-D) dPCR 2D
data plots for A. EGFR L858R/WT, B. KRASG12D/WT, C. NRASA59T/WT and D. PIK3CA
E545K/WT assays showing negative controls (plasma only, NTCs), positive controls (non-
spiked Multiplex I cfDNA Reference Standards) and analysis of full-process controls (plasma
spiked with Multiplex I cfDNA Reference Standards). Data was analysed using QuantaLife
(Bio-Rad, version 1.6.6.0320) with classification of single positive (mutant (blue), wild-type
(green)), double positive (orange) and negative (black) droplets by manual crosshair setting
(A, B, D) or lasso (C; lassos not shown by software post-analysis). E. Accepted droplet number
for all four dPCR assays.
(EPS)
S2 Fig. Sensitivity of the eTAm-Seq technology.
(AI)
S3 Fig. Evaluation of extraction efficiency using full-process control samples. Copy number
concentrations of each target in spiked extracts were quantified by dPCR and extraction effi-
ciency calculated by comparison with the values assigned by dPCR using the same assay.
(AI)
S4 Fig. Precision of eTAm-Seq technology and dPCR measurements of full-process control
materials. Precision is expressed as % coefficient of variation (%CV) for measurements of full-
process control materials spiked with 5% and 1% AF Multiplex I cfDNA Reference Standards
(n = 5 (5% Reference Standard); n = 6 (1% Reference Standard) and reflects both extraction
and analytical variability.
(AI)
S5 Fig. Analytical sensitivity of eTAm-Seq technology and dPCR measurements of full-
process control materials. Detection rate of mutant targets by eTAm-Seq technology and
dPCR in full-process control materials spiked with 5%, 1% and 0.1% AF Multiplex I cfDNA
Reference Standards expressed as number of positive measurements (n = 6).
(AI)
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S1 File. dMIQE checklist.
(PDF)
S2 File. dPCR assay validation for dMIQE review.
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S1 Table. Exonic regions covered by the InVision liquid biopsy tumor profiling panel.
(XLSX)
S2 Table. A-C. A. dPCR assay information B. dPCR assay information (custom design) C.
PCR cycling conditions.
(DOCX)
S3 Table. LOD of dPCR assays.
(DOCX)
S4 Table. Table of allele fractions (shown as percentages) for the 32 common low fre-
quency variants validated/quantified in Horizon Tru-Q 7 and in the InVision liquid biopsy
panel for both laboratories (one tab per laboratory). Rows list all combination of variants
(32 variants) and dilution levels (5 levels). Columns show the operator/repeats. The last col-
umn indicates the expected allele fraction based on dPCR data supplied by Horizon Discovery,
and the dilution level. Missing values indicate that no call was made for that combination of
variant/dilution/operator/repeat.
(XLSX)
S5 Table. List of variants analyzed in the Horizon Tru-Q 6 and Horizon Tru-Q 7 dilution
study.
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S6 Table. Sensitivity analysis for all samples.
(XLSX)
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